Successful use of dabrafenib after the occurrence of drug rash with eosinophilia and systemic symptoms (DRESS) induced by vemurafenib

• Camille Pinard, MD,
• Claire Mignard, MD,
• Agnès Samain, MD,
• Anne-Bénédicte Duval-Modeste, MD,
• Pascal Joly, MD, PhD

Affiliations

Camille Pinard, MD

Correspondence to: Camille Pinard, MD, Dermatology Department, Rouen University Hospital, 1 rue de Germont, 76031 Rouen Cedex, France.; Dermatology Department, Institute for Research and Innovation in Biomedicine, Rouen University Hospital, University of Normandie, Rouen, France

Claire Mignard, MD

Dermatology Department, Institute for Research and Innovation in Biomedicine, Rouen University Hospital, University of Normandie, Rouen, France

Agnès Samain, MD

Dermatology Department, Institute for Research and Innovation in Biomedicine, Rouen University Hospital, University of Normandie, Rouen, France

Anne-Bénédicte Duval-Modeste, MD

Dermatology Department, Institute for Research and Innovation in Biomedicine, Rouen University Hospital, University of Normandie, Rouen, France

Pascal Joly, MD, PhD

Dermatology Department, Institute for Research and Innovation in Biomedicine, Rouen University Hospital, University of Normandie, Rouen, France